PL3043803T3 - Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie - Google Patents

Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie

Info

Publication number
PL3043803T3
PL3043803T3 PL14844012.6T PL14844012T PL3043803T3 PL 3043803 T3 PL3043803 T3 PL 3043803T3 PL 14844012 T PL14844012 T PL 14844012T PL 3043803 T3 PL3043803 T3 PL 3043803T3
Authority
PL
Poland
Prior art keywords
nucleotide
nucleoside compositions
nucleoside
compositions
Prior art date
Application number
PL14844012.6T
Other languages
English (en)
Inventor
Dennis C. Liotta
George R. Painter
Gregory R. Bluemling
Abel De La Rosa
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of PL3043803T3 publication Critical patent/PL3043803T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14844012.6T 2013-09-11 2014-09-10 Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie PL3043803T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361876473P 2013-09-11 2013-09-11
US201461923317P 2014-01-03 2014-01-03
US201461986577P 2014-04-30 2014-04-30
PCT/US2014/054930 WO2015038596A1 (en) 2013-09-11 2014-09-10 Nucleotide and nucleoside compositions and uses related thereto

Publications (1)

Publication Number Publication Date
PL3043803T3 true PL3043803T3 (pl) 2022-11-07

Family

ID=52666219

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14844012.6T PL3043803T3 (pl) 2013-09-11 2014-09-10 Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie

Country Status (12)

Country Link
US (5) US10149859B2 (pl)
EP (2) EP3043803B1 (pl)
JP (4) JP6762873B2 (pl)
DK (1) DK3043803T3 (pl)
ES (1) ES2927955T3 (pl)
HR (1) HRP20220911T1 (pl)
LT (1) LT3043803T (pl)
PL (1) PL3043803T3 (pl)
SI (1) SI3043803T1 (pl)
TW (1) TW201542581A (pl)
UY (1) UY35732A (pl)
WO (1) WO2015038596A1 (pl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013174962A1 (en) 2012-05-25 2013-11-28 Janssen R&D Ireland Uracyl spirooxetane nucleosides
ES2725491T3 (es) 2012-11-16 2019-09-24 Univ College Cardiff Consultants Ltd Mezcla de RP/SP gemcitabina-[fenil-(benciloxi-L-alaninil)]-fosfato
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
AU2015280234B2 (en) * 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN117379452A (zh) 2014-06-24 2024-01-12 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
SG10202009020VA (en) 2014-11-28 2020-10-29 NuCana plc New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
SG10202013032YA (en) * 2014-12-15 2021-02-25 Univ Emory Phosphoramidates for the treatment of hepatitis b virus
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
GEAP202215528A (en) 2015-03-06 2022-11-10 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
EP3344642A1 (en) 2015-09-02 2018-07-11 AbbVie Inc. Anti-viral tetrahydrofurane derivatives
CN106674297A (zh) * 2015-11-11 2017-05-17 中国科学院生态环境研究中心 具有抗癌活性的新型krn7000类似物及合成方法
WO2017155923A1 (en) * 2016-03-07 2017-09-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
RU2752172C2 (ru) 2016-08-31 2021-07-23 Фуджифилм Корпорэйшн Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
JP7016170B2 (ja) * 2016-12-16 2022-02-04 国立大学法人東海国立大学機構 ヌクレオシド誘導体及びその利用
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
US10688112B2 (en) 2017-07-13 2020-06-23 Emory University Lipid disulfide prodrugs and uses related thereto
JP7173467B2 (ja) 2017-10-31 2022-11-16 ヤマサ醤油株式会社 ヌクレオシド誘導体及びその利用
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
MX2020006864A (es) * 2017-12-27 2020-11-11 Univ Emory Modalidades combinadas para inhibidores de nucleosidos y/o nadph oxidasa (nox) como agentes antivirales especificos de mieloides.
CN111836823B (zh) * 2018-03-09 2023-06-30 国立研究开发法人科学技术振兴机构 β修饰磷酸化合物前体、β修饰磷酸化合物、反应阻碍剂和包含这些化合物的医药品以及反应阻碍方法
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN110655546B (zh) * 2018-12-18 2023-05-16 安徽贝克制药股份有限公司 索非布韦衍生物及其制备方法和应用
CN109503688A (zh) * 2018-12-21 2019-03-22 佛山科学技术学院 具有抑制病毒复制活性的核苷磷酸长链酯类似物、制备方法及其药物用途
JP7233660B2 (ja) * 2019-04-05 2023-03-07 株式会社日本触媒 架橋型人工ヌクレオシドの製造
CN110204584B (zh) * 2019-06-17 2022-09-09 大连大学 一种4-s-2’,3’,5’-o-三乙酰基尿苷合成方法
CN110105416B (zh) * 2019-06-17 2022-07-12 大连大学 一种4-S-5-Br-2’，3’,5’-O-三乙酰基尿苷合成方法
EP4017499A4 (en) 2019-08-22 2024-01-10 Emory University Nucleoside prodrugs and uses related thereto
DK4069691T3 (da) 2019-12-06 2024-10-28 Vertex Pharma Substituerede tetrahydrofuraner som modulatorer af natriumkanaler
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4106876B1 (en) 2020-02-18 2025-09-17 Gilead Sciences, Inc. Antiviral compounds
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
KR102145197B1 (ko) * 2020-03-10 2020-08-18 부광약품 주식회사 코로나바이러스를 치료하기 위한 l-뉴클레오사이드의 용도
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
WO2022081823A1 (en) * 2020-10-14 2022-04-21 Temple University -Of The Commonwealth System Of Higher Education Pharmacologic approach for suppression of coronaviruses
CN112778356B (zh) * 2020-12-26 2022-07-01 山东日兴新材料股份有限公司 一种三(三溴新戊基)磷酸酯阻燃剂的一锅法合成工艺
CN112661802B (zh) * 2021-01-25 2022-05-13 阿里生物新材料（常州）有限公司 一种3′-甲氧基鸟苷的合成方法
TW202241454A (zh) 2021-02-01 2022-11-01 日商第一三共股份有限公司 抗體－免疫賦活化劑共軛物之新穎製造方法
KR102923359B1 (ko) 2021-04-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
CN112979733B (zh) * 2021-04-25 2021-09-10 南京颐媛生物医学研究院有限公司 抗乙肝病毒的化合物及其制备方法和应用
EP4333859A4 (en) * 2021-05-05 2025-03-26 Emory University THERAPEUTIC COMPOSITIONS CONTAINING NUCLEOTIDES AND NUCLEOSIDES, COMBINATIONS AND USES THEREOF
MA64853B1 (fr) 2021-06-04 2025-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hétéro)aryl) tétrahydrofuran carboxamides utilisés en tant que modulateurs de canaux sodiques
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
CN113278041B (zh) * 2021-07-16 2021-10-19 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法与抗肝炎病毒的制药应用
EP4387977A1 (en) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN113501853B (zh) * 2021-09-13 2021-12-07 南京颐媛生物医学研究院有限公司 4-硫代尿嘧啶脱氧核苷磷酸酯及其抗病毒药物用途
CN113735927B (zh) * 2021-10-18 2024-06-28 厦门蔚扬药业有限公司 一种核苷酸类似物及其制备方法和用途
WO2023086557A1 (en) * 2021-11-11 2023-05-19 Emory University Nucleosides for the treatment of dna virus infections
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN118591377A (zh) * 2022-01-26 2024-09-03 加利福尼亚大学董事会 抗病毒前药、中效和长效制剂和方法
CN116554249B (zh) * 2022-01-28 2025-03-18 北京恩泰伟医药科技有限公司 抗病毒化合物及其用途
JP2025509635A (ja) 2022-03-15 2025-04-11 ローム・セラピューティクス・インコーポレイテッド 疾患を治療するための化合物及び方法
WO2023178228A1 (en) * 2022-03-16 2023-09-21 Pharmalectin, Inc. Lectin-binding carbohydrates for treating viral infections
EP4248949B1 (en) 2022-03-21 2024-08-28 R.G.C.C. Holdings AG Liposomal compositions
JP7679129B2 (ja) * 2022-07-12 2025-05-19 南京工▲業▼大学 コルジセピンの誘導体化による抗腫瘍効果を有する化合物
WO2024137577A1 (en) * 2022-12-19 2024-06-27 Ohio State Innovation Foundation Multiparametric integrated molecular detection of viral antigens and viral nucleic acids
WO2024167952A1 (en) * 2023-02-08 2024-08-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oxidatively cleavable organophosphate drugs
WO2024249234A1 (en) * 2023-05-26 2024-12-05 Altesa BioSciences, Inc. Method of treating hepatitis c virus in patients
WO2025058573A1 (en) * 2023-09-15 2025-03-20 National Science And Technology Development Agency Cordycepin derivatives or a pharmaceutically acceptable salt thereof as pan-antiviral agents

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3404144A (en) * 1965-12-23 1968-10-01 Research Corp 1-beta-d-arabinofuranosyl-5-fluorocytosine compounds
DE2041735A1 (de) * 1970-08-22 1972-02-24 Merck Patent Gmbh Thio-pyrimidin-derivate
US3975374A (en) * 1970-12-21 1976-08-17 The Upjohn Company Process for preparing 2-thiouracil nucleosides
JPS4947379A (pl) * 1972-09-12 1974-05-08
PL107865B1 (pl) 1977-04-27 1980-03-31 Polska Akademia Nauk Instytut Method of obtaining styrene oxide sposob otrzymywania tlenku styrenu
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US4954485A (en) * 1987-10-20 1990-09-04 Sanyo-Kokusaku Pulp Co., Ltd. 2',3'-dideoxy-4-thio-uridine derivatives, process for their preparation and antivirus agents using them
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
DK0831852T3 (da) 1995-06-07 2007-03-19 Univ Emory Nukleosider med anti-hepatitis B-virusaktivitet
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
JPH107694A (ja) * 1996-06-21 1998-01-13 Toagosei Co Ltd ３’−アミノ−２−チオピリミジンヌクレオシド
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6610835B1 (en) 1998-02-12 2003-08-26 Emory University Sphingolipid derivatives and their methods of use
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6461422B1 (en) * 2000-01-27 2002-10-08 Chartpak, Inc. Pressure sensitive ink jet media for digital printing
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス（ケイマン）リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP1346724A4 (en) 2000-12-26 2004-11-17 Mitsubishi Pharma Corp AGENT FOR TREATING HEPATITIS C
US20040006002A1 (en) * 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
WO2003026589A2 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
PL197669B1 (pl) * 2002-02-28 2008-04-30 Pan Inst Biochemii I Biofizyki Nowe analogi 2',3'-dideoksy-3'-fluorotymidyny o aktywności przeciwko wirusom (54) ludzkiego niedoboru immunologicznego HIV-1 i HIV-2, sposób ich wytwarzania oraz zawierające je środki farmaceutyczne
US20040063658A1 (en) 2002-05-06 2004-04-01 Roberts Christopher Don Nucleoside derivatives for treating hepatitis C virus infection
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
US20040035547A1 (en) 2002-08-20 2004-02-26 3M Innovative Properties Company Metal matrix composites, and methods for making the same
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2006121820A1 (en) * 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
RU2441869C2 (ru) 2005-12-21 2012-02-10 Эбботт Лэборетриз Противовирусные соединения
HUP0600042A3 (en) 2006-01-19 2012-12-28 Debreceni Egyetem New medical use of thiolated pyrimidine-mononucleotides and -nucleosides
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CN105693626A (zh) 2007-09-17 2016-06-22 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN102746239B (zh) 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
RU2552533C2 (ru) 2009-03-25 2015-06-10 Эббви Инк. Противовирусные соединения и их применения
CN105924386A (zh) 2009-03-25 2016-09-07 Abbvie 公司 抗病毒化合物和其用途
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
UA118080C2 (uk) 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
AU2011224558B2 (en) 2010-03-10 2014-02-27 Abbvie Ireland Unlimited Company Solid compositions
US8691775B2 (en) * 2010-04-19 2014-04-08 Back Bay Scientific, Llc Use of drugs that activate P2Y receptors to enhance synaptogenesis
EP2576564A4 (en) 2010-06-07 2014-01-22 Abbvie Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
EP3056486B1 (en) 2010-07-16 2018-07-11 AbbVie Ireland Unlimited Company Process for preparing intermediates for antiviral compounds
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
TWI451439B (zh) 2010-12-10 2014-09-01 Phison Electronics Corp 記憶體儲存裝置、其記憶體控制器與資料寫入方法
CN103384664A (zh) 2010-12-16 2013-11-06 Abbvie公司 抗病毒化合物
EP2651885A1 (en) 2010-12-16 2013-10-23 Abbvie Inc. Anti-viral compounds
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3043803B1 (en) * 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
SG10202013032YA (en) * 2014-12-15 2021-02-25 Univ Emory Phosphoramidates for the treatment of hepatitis b virus

Also Published As

Publication number Publication date
EP3043803B1 (en) 2022-04-27
US20160220595A1 (en) 2016-08-04
TW201542581A (zh) 2015-11-16
US20190298750A1 (en) 2019-10-03
LT3043803T (lt) 2022-08-10
JP7045411B2 (ja) 2022-03-31
US20240173345A1 (en) 2024-05-30
US20220296626A1 (en) 2022-09-22
HRP20220911T1 (hr) 2022-10-28
JP2024123107A (ja) 2024-09-10
US11857560B2 (en) 2024-01-02
JP2016530313A (ja) 2016-09-29
EP3043803A4 (en) 2017-03-29
WO2015038596A1 (en) 2015-03-19
DK3043803T3 (da) 2022-08-01
US20260053838A1 (en) 2026-02-26
JP2020143073A (ja) 2020-09-10
UY35732A (es) 2015-06-30
SI3043803T1 (sl) 2022-09-30
JP7508501B2 (ja) 2024-07-01
US10149859B2 (en) 2018-12-11
EP3043803A1 (en) 2016-07-20
ES2927955T3 (es) 2022-11-14
US12414961B2 (en) 2025-09-16
JP6762873B2 (ja) 2020-09-30
JP2022081641A (ja) 2022-05-31
EP4094767A1 (en) 2022-11-30
US11166973B2 (en) 2021-11-09

Similar Documents

Publication Publication Date Title
PL3043803T3 (pl) Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
EP2953474A4 (en) COMPOSITIONS AND METHODS
IL239324B (en) Substituted nucleosides, nucleotides and analogs thereof
IL237849B (en) Ret inhibitors and uses of same
BR112015028459A2 (pt) composições e comestíveis
PL3035936T3 (pl) Pewne jednostki chemiczne, kompozycje i sposoby
GB201313235D0 (en) Antiviral Compositions Methods and Animals
PL2978419T3 (pl) Kompozycje do zwiększania żywotności komórek i metody ich stosowania
EP3065716C0 (en) FORMULATIONS
ME03502B (me) Supstituisani nukleozidi, nukleotidi i njihovi analozi
EP2889350A4 (en) ADHESIVE COMPOSITION
EP2989885A4 (en) HARVESTER
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
EP2970569A4 (en) PERSISTENT CARBENE AND COMPOSITIONS WITH IT
EP3039131C0 (en) ENZYME COMPOSITION AND USES
DK3027750T3 (da) Biokatalytisk sammensætning
PL3030519T3 (pl) Trójpierścieniowe związki benzoksaborolu i ich zastosowania
BR112015001562A2 (pt) biotinas e composições
ZA201507045B (en) Uridine nucleoside derivatives, compositions and methods of use
HRP20181291T1 (hr) Heterobicikloarilni inhibitori rorc2 i njihova upotreba
PL3042669T3 (pl) Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy
PL3055307T3 (pl) Podstawione berbiny i ich synteza
DK3068428T3 (da) Annexin-ii-variant-sammensætninger og fremgangsmåder
FR3007291B1 (fr) Composition cicatrisante et utlisation